Vaccination reduced risk of heart failure and some clot-related complications for up to a year

The risk of cardiac and clot-related complications following COVID-19 is substantially reduced in people who receive the COVID-19 vaccination compared with unvaccinated individuals, reports an observational study published online in the journal Heart.

COVID-19 vaccines proved to be highly effective in reducing the severity of acute SARS-CoV-2 infection, COVID-19-related hospital admission and death.

And while some COVID-19 vaccines were associated with increased risk of rare but serious complications, such as blood clots and heart inflammation (myocarditis), the risk of these complications was substantially higher after SARS-CoV-2 infection.

Some studies have suggested that vaccination could protect against these complications of COVID-19, but most did not include long-term complications and were focused on specific populations.

To address this, researchers set out to study the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications using population data for the UK, Spain and Estonia which included 10.17 million vaccinated people and 10.39 million unvaccinated people.

Individuals who were vaccinated received either an adenovirus-based vaccine (Oxford/AstraZeneca or Janssen) or one of the mRNA vaccines (BioNTech/Pfizer or Moderna).

The researchers identified cases of cardiac and thromboembolic complications in the first year after SARS-CoV-2 infection and recorded them according to four post-infection time windows: 0–30, 31–90, 91–180 and 181–365 days after infection.

A range of potentially influential factors, such as age, sex and pre-existing conditions including chronic lung disease, diabetes, heart disease and a history of blood clots were accounted for in the analysis to minimise bias.

The results show that COVID-19 vaccination was associated with reduced risks of heart failure, venous thromboembolism (clot within the veins of a limb) and arterial thrombosis/thromboembolism (blood clot in the artery) for up to a year after SARS-CoV-2 infection.

Reduced risk of other complications, such as ventricular arrhythmia/cardiac arrest (heart attack), myocarditis/pericarditis were also seen but only in the acute phase (first 30 days after infection).

Compared with unvaccinated individuals, having COVID-19 vaccination was associated with reduced risks of venous thromboembolism by 78%, arterial thrombosis/thromboembolism by 47% and heart failure by 55% in the first 30 days after SARS-CoV-2 infection.

As time progressed, the protective effects of vaccination waned, but remained at 47%, 28%, and 39% respectively at 91–180 days after infection and 50%, 38%, and 48% respectively at 181-365 days.

This is an observational study, so can’t establish cause and effect, and the authors highlight some limitations including the inherent data quality concerns and risk of bias with use of real-world data, and potential under-reporting of post-COVID-19 complications.

However, state-of-the-art statistical methods were used to deal with these limitations and results were consistent across all databases, which they say highlights the robustness and replicability of the findings.

As such, they conclude, “Our analyses showed a substantial reduction of risk (42–82%) for thromboembolic and cardiac events in the acute phase of COVID-19 associated with vaccination.”

They add, “Reduced risk in vaccinated people lasted for up to 1 year for post-COVID-19 venous thromboembolism, arterial thrombosis/thromboembolism and heart failure, but not clearly for other complications.”

The authors suggest that the protective effects of vaccination are “consistent with known reductions in disease severity following breakthrough versus unvaccinated SARS-CoV-2 infection” and say further research is needed on the possible waning of the effect over time and on the impact of booster vaccination.



Notes for editors

Research: The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications doi:10.1136/heartjnl-2023-323483

Journal: Heart

Funding: National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre (BRC), and some database research costs were covered by the Real World Epidemiology (RWEpi) research group at IDIAPJGol and the European Health Data and Evidence Network (EHDEN).

Link to AMS labelling system

Peer reviewed? Yes

Evidence type: Observational

Subjects: People